Daniel Dubin - 23 Dec 2021 Form 4/A - Amendment Insider Report for PARDES BIOSCIENCES, INC.

Role
Director
Signature
/s/ Dennis Ryan, as Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
23 Dec 2021
Net transactions value
$0
Form type
4/A - Amendment
Filing time
30 Dec 2021, 15:00:20 UTC
Date Of Original Report
28 Dec 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PRDS Class A Common Stock Conversion of derivative security $0 +30,000 $0.000000 30,000 23 Dec 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PRDS Class B Common Stock Conversion of derivative security $0 -30,000 -100% $0.000000* 0 23 Dec 2021 Class A Common Stock 30,000 $0.000000 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Daniel Dubin is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 In connection with the closing of Pardes Biosciences, Inc.'s (formerly known as FS Development Corp. II) business combination, shares of Class B Common Stock of FS Development Corp. II converted into shares of Class A Common Stock of the Issuer.

Remarks:

On December 28, 2021, the reporting person filed a Form 4 which contained a clerical error reporting that the reporting person beneficially owned 52,500 shares of Class B Common Stock of FS Development Corp. II prior to its business combination. In fact, as reported in this Form 4, the reporting person beneficially owned 30,000 shares of Class B Common Stock.